Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
PHARMABCINE INC
{{company.company_channel.channel_name}}
Media Room
Latest
Photos
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020
2020-11-16 21:00
PharmAbcine to participate at BIO-Europe 2020
2020-10-23 20:00
PharmAbcine expands partnership with Samsung Biologics for PMC-403
2020-09-21 20:00
PharmAbcine Unveils Olinvacimab's Positive Results from Phase Ib Combination Studies at KSMO 2020
2020-09-14 20:00
PharmAbcine is presenting at the KSMO 2020
2020-09-02 21:00
PharmAbcine signs a CMO contract with Binex so Binex can produce olinvacimab at its new 5,000L production line
2020-09-02 21:00
PharmAbcine announces the execution of a Material Cooperative Research and Development Agreement (MCRADA) with the NIH to evaluate the efficacy of PMC-403 to treat SCLS
2020-08-18 21:00
PharmAbcine signs a research collaboration agreement with Wuxi Shuangliang Biotechnology (SLBio) to evaluate a combination therapy to treat NSCLC
2020-08-03 21:00
PharmAbcine Signs Long-term Contract Manufacturing Organization Agreement for Olinvacimab with Binex
2020-06-27 00:00
PharmAbcine execute an agreement with Thermo Fisher for the development and manufacturing of its next-generation immune checkpoint blockade, PMC-309 for Phase I
2020-06-11 00:00
PharmAbcine signs a license agreement with Wincal Biopharm to expand indications of PharmAbcine's existing assets to non-oncology areas
2020-06-04 00:00
1
2
3